Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 10/20 | 0.57 |
| ▸ | CTSL | P07711 | 8/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | GRN | P28799 | 2/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924662 | 0.93 | CTSB (0.60) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924665 | 0.93 | CTSB (0.60) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924748 | 0.91 | CTSB (0.48) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924645 | 0.90 | CTSB (0.52) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924642 | 0.90 | CTSB (0.52) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924689 | 0.89 | CTSB (0.58) | CTSBCTSLCTSKCTSSHPGDS | |
| SCHEMBL5924798 | 0.88 | CTSB (0.59) | CTSBCTSLCTSKCTSSKDM4E | |
| SCHEMBL5925027 | 0.87 | CTSB (0.58) | CTSBCTSLCTSKCTSS | |
| SCHEMBL5924915 | 0.87 | CTSB (0.60) | CTSBCTSLCTSKCTSSGRN | |
| SCHEMBL5924692 | 0.86 | CTSB (0.46) | CTSBCTSLCTSKCTSSGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | CTSB 2/4885CTSL 11/4885CTSK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.